Tarsus Pharmaceuticals, Inc.
TARS
株式のランク
#4596
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
株価
$71.12
最終同期: 2026-10-20
時価総額
$3.33B
変化（1日）
2.33%
変化（1年）
0.42%
国
US
取引 Tarsus Pharmaceuticals, Inc. (TARS)
カテゴリー
Healthcare
Tarsus Pharmaceuticals, Inc.（TARS）のP/B比率
October 2026 時点のP/B比率 TTM: 9.05
Tarsus Pharmaceuticals, Inc. の最新の財務報告および株価によると、現在のP/B比率（TTM）は 9.05 です。2023 年末時点でのP/B比率は 3.02 でした。
Tarsus Pharmaceuticals, Inc. の P/B 比率の履歴（2018 ～ 2026）
各年末時点のP/B比率
| 年 | P/B比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 9.05 | -2.40% |
| 2024 | 9.27 | 207.02% |
| 2023 | 3.02 | 61.44% |
| 2022 | 1.87 | -32.54% |
| 2021 | 2.77 | -45.19% |
| 2020 | 5.06 | -107.57% |
| 2019 | -66.86 | 2.65% |
| 2018 | -65.13 | 0.00% |
同業他社のP/B比率
| 企業 | P/B比率 | P/B比率の差 | 国 |
|---|---|---|---|
| 6.251 | -30.91% |
US
|
|
| 13.2547 | 46.51% |
US
|
|
| 4.208 | -53.49% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -31.66% |
NL
|
